Gastrointestinal stromal tumor surgery and adjuvant therapy

Valerie P. Grignol, Paula M. Termuhlen

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GIST) are a unique class of mesenchymal tumors identified within the past decade. Intense molecular and genetic study has been used to characterize these tumors and develop treatment strategies. Although the mainstay of treatment remains surgical resection, therapy targeted at inhibiting tyrosine kinases has had dramatic results. Because of the rapid accumulation of information about the diagnosis and treatment of these tumors, the National Comprehensive Cancer Network convened a GIST task force to provide updated recommendations in 2010. As understanding of these tumors advances, rapid changes in recommendations will continue and should warrant regular updates in tumor management.

Original languageEnglish (US)
Pages (from-to)1079-1087
Number of pages9
JournalSurgical Clinics of North America
Volume91
Issue number5
DOIs
StatePublished - Oct 1 2011

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Therapeutics
Advisory Committees
Protein-Tyrosine Kinases
Molecular Biology

Keywords

  • GIST
  • Gastrointestinal stromal tumor
  • Imatinib mesylate
  • KIT
  • PDGFRA

Cite this

Gastrointestinal stromal tumor surgery and adjuvant therapy. / Grignol, Valerie P.; Termuhlen, Paula M.

In: Surgical Clinics of North America, Vol. 91, No. 5, 01.10.2011, p. 1079-1087.

Research output: Contribution to journalReview article

@article{beee4d8f5ed84ee2a20fa64f45098347,
title = "Gastrointestinal stromal tumor surgery and adjuvant therapy",
abstract = "Gastrointestinal stromal tumors (GIST) are a unique class of mesenchymal tumors identified within the past decade. Intense molecular and genetic study has been used to characterize these tumors and develop treatment strategies. Although the mainstay of treatment remains surgical resection, therapy targeted at inhibiting tyrosine kinases has had dramatic results. Because of the rapid accumulation of information about the diagnosis and treatment of these tumors, the National Comprehensive Cancer Network convened a GIST task force to provide updated recommendations in 2010. As understanding of these tumors advances, rapid changes in recommendations will continue and should warrant regular updates in tumor management.",
keywords = "GIST, Gastrointestinal stromal tumor, Imatinib mesylate, KIT, PDGFRA",
author = "Grignol, {Valerie P.} and Termuhlen, {Paula M.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.suc.2011.06.007",
language = "English (US)",
volume = "91",
pages = "1079--1087",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Gastrointestinal stromal tumor surgery and adjuvant therapy

AU - Grignol, Valerie P.

AU - Termuhlen, Paula M.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Gastrointestinal stromal tumors (GIST) are a unique class of mesenchymal tumors identified within the past decade. Intense molecular and genetic study has been used to characterize these tumors and develop treatment strategies. Although the mainstay of treatment remains surgical resection, therapy targeted at inhibiting tyrosine kinases has had dramatic results. Because of the rapid accumulation of information about the diagnosis and treatment of these tumors, the National Comprehensive Cancer Network convened a GIST task force to provide updated recommendations in 2010. As understanding of these tumors advances, rapid changes in recommendations will continue and should warrant regular updates in tumor management.

AB - Gastrointestinal stromal tumors (GIST) are a unique class of mesenchymal tumors identified within the past decade. Intense molecular and genetic study has been used to characterize these tumors and develop treatment strategies. Although the mainstay of treatment remains surgical resection, therapy targeted at inhibiting tyrosine kinases has had dramatic results. Because of the rapid accumulation of information about the diagnosis and treatment of these tumors, the National Comprehensive Cancer Network convened a GIST task force to provide updated recommendations in 2010. As understanding of these tumors advances, rapid changes in recommendations will continue and should warrant regular updates in tumor management.

KW - GIST

KW - Gastrointestinal stromal tumor

KW - Imatinib mesylate

KW - KIT

KW - PDGFRA

UR - http://www.scopus.com/inward/record.url?scp=80052235397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052235397&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2011.06.007

DO - 10.1016/j.suc.2011.06.007

M3 - Review article

C2 - 21889030

AN - SCOPUS:80052235397

VL - 91

SP - 1079

EP - 1087

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 5

ER -